CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received an average recommendation of “Hold” from the twenty-one research firms that are currently covering the stock, MarketBeat.com reports ...

CRISPR Therapeutics (NasdaqGM:CRSP) experienced an 12% price decline over the last week, coinciding with significant market disruption driven by escalating tariff tensions, which saw the S&P 500 and ...

Of the pure-play gene editing specialists on the market, CRISPR Therapeutics (NASDAQ: CRSP) is one of the more prominent. CRISPR Therapeutics (NasdaqGM:CRSP) experienced an 12% price decline over ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Learn more about whether CRISPR Therapeutics AG or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Recursion Pharmaceuticals uses artificial intelligence (AI) in its proprietary operating system to match new compounds ...

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $32.65, marking a -0.03% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 5.98%.

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...

Synthego and Vita Therapeutics sign licensing agreement for high-fidelity nucleases designed for therapeutic applications, hfCas12Max CRISPR system: Redwood City, California Wedne ...

Learn more about whether Alvotech or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which ...